Seres Therapeutics, Inc.
MCRB
$6.33
$0.050.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -46.90M | 5.70M | 5.39M | 85.97M | 72.95M |
| Total Depreciation and Amortization | 12.24M | 12.53M | 13.46M | 13.82M | 14.19M |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 463.00K | 948.00K |
| Total Other Non-Cash Items | 9.83M | 10.67M | 10.47M | -109.87M | -106.48M |
| Change in Net Operating Assets | -17.32M | -27.78M | -52.38M | -50.33M | -68.07M |
| Cash from Operations | -42.15M | 1.12M | -23.06M | -59.94M | -86.46M |
| Capital Expenditure | -218.00K | -252.00K | -313.00K | -434.00K | -352.00K |
| Sale of Property, Plant, and Equipment | 210.00K | 210.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 0.00 | 141.27M | 141.27M |
| Other Investing Activities | -- | -- | 0.00 | 0.00 | 1.40M |
| Cash from Investing | -8.00K | -42.00K | -313.00K | 140.84M | 142.32M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | -127.91M | -127.91M |
| Issuance of Common Stock | 13.15M | 13.90M | 2.98M | 19.95M | 19.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13.15M | 13.90M | 2.98M | -107.95M | -107.95M |
| Foreign Exchange rate Adjustments | -- | -- | -1.00K | -1.00K | -1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.02M | 14.97M | -20.39M | -27.06M | -52.10M |